Kaposi sarcoma associated with rituximab-based cytotoxic therapy

Alkan A., Yasar A., TOPRAK S.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.1, pp.220-223, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 26 Issue: 1
  • Publication Date: 2020
  • Doi Number: 10.1177/1078155219835592
  • Journal Name: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Agricultural & Environmental Science Database, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
  • Page Numbers: pp.220-223
  • Keywords: Rituximab, Kaposi sarcoma, lymphoma, HHV-8
  • Ankara University Affiliated: Yes

Abstract

Kaposi sarcoma (KS) is a low-grade mesenchymal angioproliferative disease, mostly observed in immune compromised patients. KS is mostly encountered in HIV-positive or organ transplant patients. The drugs causing immunosuppression have also been associated with KS. Here, we present a KS experience associated with rituximab-based therapy.